Fact
₹100 Cr has been raised in a first institutional round by the contract manufacturer supplying Nykaa, Plum, Pilgrim and Bare Anatomy, led by Sharrp Ventures, with Mirabilis Investment Trust (the family office of Infosys co-founder K. Dinesh), Anicut Capital, Niveshaay, and angels from pharma and specialty chemicals also participating, per Entrackr. Note the correction to Edition 021's coverage: the ₹33.74 Cr figure cited there came from an RoC filing that captured only part of the round, the actual closed round is roughly three times that size.
Interpretation
Look at who wrote the cheques: a marquee FMCG family office, a tech-wealth family office, and operator-angels from pharma and specialty chemicals, exactly the investor profile that buys infrastructure, not brand stories. Indian beauty's picks-and-shovels layer is getting institutional capital at the same moment brand-layer valuations are being questioned, and the same week AI citation data (Edition 022) showed formulation-led positioning winning discovery. Capital is moving one level down the stack, toward whoever makes the formulations every brand depends on.
Action
Brands manufacturing with Naturis, or any shared contract manufacturer, should treat this raise as a capacity event with a concentration catch: more lines are coming, but so are more competitor SKUs through the same facility. Ask your manufacturer two questions this month: what share of new capacity is reserved for existing clients, and what does a dedicated-line commitment cost at your volume.
Watch next
Whether Sharrp follows this with more manufacturing-layer bets, and whether Naturis moves toward its own IP formulations, the step where a contract manufacturer starts competing with its clients.